Fundraising FoxTurn Therapeutics
Westlake Village, US
Find your way into Turn Therapeutics
518 people in our graph share verified history with the Turn Therapeutics team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Bradley Burnam · together at Stanford University (overlapped)
×11knows the team · via Stanford University
Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
Founders & leadership
BB
Bradley BurnamFounder/Chief Executive OfficerBradley Burnam founded Turn Therapeutics, which develops topical therapies for inflammatory skin and infectious diseases using its proprietary PermaFusion drug delivery platform.
ZC
Zuraiz ChaudharyExecutive
NS
Neilesh Shailesh GhodadraExecutive
Board
MW
Martin William DewhurstBoard director
AG
Andrew GengosBoard director
AF
Arthur F GoldenBoard director
KK
Kent KesterBoard director
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2026
▶$1.6MraisedAug 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.6MraisedAug 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bradley BurnamExecutive Officer, Director
- Zuraiz ChaudharyExecutive Officer
- Martin William DewhurstDirector
- Andrew GengosDirector
- Arthur F GoldenDirector
- Kent KesterDirector
- Neilesh Shailesh GhodadraExecutive Officer, Director
- Amount sold
- $1.6M
- Minimum investment
- $15K
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Turn Therapeutics do?
- Turn Therapeutics develops topical therapies for skin diseases using its proprietary PermaFusion drug delivery platform. The company's lead program, GX-03, is designed to treat moderate to severe eczema by reducing IL-36 signaling and downstream inflammatory cytokines.
- Who founded Turn Therapeutics?
- Turn Therapeutics was founded by Bradley Burnam.
- How much funding has Turn Therapeutics raised?
- Turn Therapeutics has disclosed $1.6M raised across 1 round.
- Where is Turn Therapeutics headquartered?
- Turn Therapeutics is headquartered in Westlake Village, US.